SCHEMBL10315908

SCHEMBL10315908

Nc1nc(-c2ccc(F)c(O)c2F)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 6/20 0.56
TYR P14679 1/20 0.54
ALDH1A1 P00352 5/20 0.46
RAB9A P51151 3/20 0.46
LTA4H P09960 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
ALOX5 P09917 1/20 0.46
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 3/20 0.43
AR P10275 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
FBP1 P09467 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474342 0.84 MPL (0.61) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL10315909 0.81 TYR (0.60) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL10087321 0.80 MPL (0.56) MPLTYRALDH1A1RAB9AALOX5
SCHEMBL474214 0.80 MPL (0.56) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL2517425 0.78 MPL (0.67) MPLTYRALDH1A1RAB9AALOX5
SCHEMBL29689702 0.78 MPL (0.60) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL15417598 0.78 MPL (0.53) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL474187 0.78 MPL (0.60) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL1801511 0.77 MPL (0.63) MPLTYRALDH1A1RAB9ALTA4H
SCHEMBL10315919 0.77 TYR (0.73) MPLTYRALDH1A1RAB9ALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 MPL 3150/4885TYR 498/4885ALDH1A1 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.